This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AERI Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Aerie Pharmaceuticals Stock (NASDAQ:AERI) Get Aerie Pharmaceuticals alerts:Sign Up Key Stats Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina. Read More Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AERI Stock News HeadlinesNeurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of DirectorsSeptember 2, 2025 | finance.yahoo.comROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsightMarch 25, 2025 | finance.yahoo.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.October 17 at 2:00 AM | Banyan Hill Publishing (Ad)US to donate 1 million mpox vaccine doses to halt outbreak in AfricaSeptember 26, 2024 | reuters.comGlobal $20B+ Macular Degeneration Treatment Market Outlook, 2024-2029: AI Integration Paves the Way for Personalized CareMay 10, 2024 | finance.yahoo.com20 Countries With Worst Vision ProblemsFebruary 29, 2024 | uk.finance.yahoo.comParatus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive OfficerFebruary 21, 2024 | finance.yahoo.comJustin Timberlake is ready to Rock Your Body for one night only in Memphis, and for freeJanuary 12, 2024 | msn.comSee More Headlines AERI Stock Analysis - Frequently Asked Questions How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The firm had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.13 million. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Bristol Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE) and Melinta Therapeutics (MLNT). Company Calendar Last Earnings11/04/2021Today10/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AERI CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year Founded2005Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.81 million Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AERI) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerie Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
